Acadia to present Phase 2 remlifanserin data in Alzheimer's psychosis at CTAD 2026

ACAD•2026-11-09

Acadia Pharmaceuticals will present Phase 2 remlifanserin findings in Alzheimer's disease psychosis at CTAD in Boston on November 16-19, 2026.

1. Conference presentations

The ongoing RADIANT trial's efficacy and safety findings are scheduled for an oral presentation on November 17 at 9:35 a.m. ET. A separate poster on biomarker heterogeneity in clinically diagnosed Alzheimer's disease psychosis patients negative for amyloid proteinopathy and p-Tau217 is scheduled for November 18.

Acadia to present Phase 2 remlifanserin data in Alzheimer's psychosis at CTAD 2026

1. Conference presentations

Related News

CN Energy director Jian Chen resigns from board and committees

Ur-Energy starts full operations at Shirley Basin uranium mine

H&R Block publishes fiscal 2027 first-quarter results call transcript

Rocket Lab shares dip on wider-than-expected quarterly loss

Dave & Buster's grants director James P. Chambers 2,236 restricted stock units